
AMR: A ‘silent pandemic' that must be addressed
PETALING JAYA: It started as a simple cough, but in just two weeks, the patient ended up at the Intensive Care Unit (ICU).
'After suffering from coughing for two weeks, my father had a seizure. And the culprit was identified as K. pneumoniae,' said virologist Dr Jasmine E. Khairat. K. pneumoniae is a bacteria with increased resistance to antibiotics.
Dr Jasmine's father had to spend another two weeks in hospital before being able to beat the 'superbug' – or bacteria resistant to drugs.
Some bacteria have grown more resistant to antibiotics, in a situation known as antimicrobial resistance (AMR), making infections harder to treat.
According to the Health Ministry, besides K. pneumoniae, another bacteria known as Escherichia coli (E. coli), which causes wound and urinary tract infections, has also shown increased resistance in Malaysia.
'AMR is a significant threat to public health and the nation's socio-economic well-being,' said Dr Jasmine, the microbiology unit assistant coordinator at the Universiti Malaya (UM) Centre for Natural Product and Drug Discovery.
She said the level of antibiotic resistance varies among superbugs and across different regions and healthcare facilities within Malaysia. 'This is why continuous surveillance is crucial,' she said.
Dr Jasmine said while it is good that Malaysia has plans for AMR, it needs to be continuously tracked and evaluated.
'There should also be more surveillance by expanding systems across human, animal and environmental sectors to track AMR trends and antibiotic usage for informed policy and interventions,' she said.
Unfortunately, granular data is lacking when it comes to AMR in Malaysia, said Universiti Sultan Zainal Abidin's Prof Dr Yeo Chew Chieng, whose expertise includes bacteriology as well as molecular and structural biology.
He said there is a need for better genomic surveillance, which is the process of monitoring pathogens and studying their genetic similarities and differences.
Likening it to knowing the various Covid-19 variants, Prof Yeo said Malaysia needs such information on the various bacteria and their lineages so there can be clearer policies on which antibiotics to prescribe.
'If we don't know the type of bacteria that are causing infections, it will be very difficult to counter this threat.
'We have to do something now if we don't want to face an 'antibiotic apocalypse' (a situation where bacterial infections are untreatable).
'The number of new antibiotics being developed are coming in a trickle, and we need to avoid being outpaced by AMR,' he said.
Prof Yeo said giving livestock antibiotics to prevent diseases and promote growth could be a dangerous practice.
'Many studies have shown that bacteria from livestock and animals could be reservoirs for not only potential bacterial pathogens but also AMR genes,' he said.
UM faculty of science institute of biological sciences senior lecturer Dr Muhamad Afiq Aziz said AMR is like a silent pandemic that demands urgent and collective attention from everyone.
'If we consider the potential impact on global health, the threat posed by AMR is comparable to major diseases like cancer and infectious diseases,' he said.
He called on the government to invest in research and development of alternatives to antibiotics, such as bacteriophages (viruses that target and kill bacteria) and antivirulence agents, which work by disarming bacteria rather than killing them.
'These agents target factors like toxins and enzymes that make bacteria harmful.
'This search for antivirulence compounds is part of my ongoing research sponsored by the Higher Education Ministry.
'We hope it can contribute meaningfully to the broader fight against AMR,' he said.
Dr Muhamad Afiq said each time an antibiotic is used, an environment is created where bacteria that can withstand the drug survive.
'These survivors, often carrying the resistance genes, then multiply and spread.
'If we use fewer antibiotics in general, we give fewer bacteria the chance to develop and pass on resistance,' he said.
Ultimately, Malaysians can also do their part in preventing AMR, said the Health Ministry.
'One of the most effective ways to reduce the need for antimicrobials is by preventing infections before they occur.
'This includes getting vaccinated, practising good personal hygiene and ensuring food is handled and prepared safely,' it said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
16 hours ago
- The Star
Proper DRG roll out can take more than six months, says private hospitals association
KUALA LUMPUR: A proper rollout of the diagnosis-related group (DRG) payment model could take more than six months given the complexities in data gathering and analysis, says the Association of Private Hospitals Malaysia (APHM), adding that it is ready to provide any help. Its president Datuk Dr Kuljit Singh said accurate clinical data and a national electronic health record system is needed for any DRG-type mechanism to work He said this foundational data is not available yet. "As the process of gathering and analysing such data is complex and time-consuming, APHM anticipates that a proper rollout will require considerably more than six months," he said. Dr Kuljit also said the APHM welcomed Health Minister Datuk Seri Dr Dzulkefly Ahmad's announcement that a basic medical and health insurance/takaful product would be introduced later this year and the DRG rolled out in phases. To support this national initiative, Dr Kuljit said APHM member hospitals have offered to share relevant clinical data with the Health Ministry and the Finance Ministry. "APHM strongly advocates that adequate time and resources are allocated to ensure that the DRG initiative is thoroughly conceptualised, piloted and implemented, to ultimately deliver sustainable improvements for all Malaysians," he said. The DRG payment system involves paying a fixed sum based on the diagnosis and treatment provided, rather than itemising each charge. It is said the DTG model can help regulate medical costs by limiting excessive charges. Examples of countries that have implemented this are Sweden, Canada and Australia. Earlier, in his opening speech, Dr Dzulkefly said introducing DRG in phases to pay for healthcare services, beginning with the base medical and health insurance/takaful products, would be a key driver for value-based healthcare. He also said the Health Ministry is hoping to introduce the DRG payment model by the end of 2025.
![[UPDATED] Malaysia's health spending jumps 4 times in 20 years](/_next/image?url=https%3A%2F%2Fassets.nst.com.my%2Fimages%2Farticles%2FDzulkefly_Ahmadwe_1749435876.jpg&w=3840&q=100)
![[UPDATED] Malaysia's health spending jumps 4 times in 20 years](/_next/image?url=https%3A%2F%2Fassets.nst.com.my%2Fassets%2FNST-Logo%402x.png%3Fid%3Db37a17055cb1ffea01f5&w=48&q=75)
New Straits Times
17 hours ago
- New Straits Times
[UPDATED] Malaysia's health spending jumps 4 times in 20 years
KUALA LUMPUR: Malaysia's per capita health expenditure nearly quadrupled between 2000 and 2020. Health Minister Datuk Seri Dr Dzulkefly Ahmad said the figure surged from RM600 in 2000 to RM1,600 in 2020, driven by rising demand for healthcare and advances in medical technology. "Private sources accounted for RM40 billion, or 47 per cent, of total health expenditure in 2024. "Out-of-pocket spending remains high, at around 36 per cent of total health expenditure. "Our vision is to sustainably expand fiscal space while ensuring healthcare remains accessible, high-quality, and equitable," he said at the launch of the 31st Association of Private Hospitals Malaysia (APHM) International Healthcare Conference & Exhibition 2025, here, today. Dzulkefly said the Health Ministry was working with the Finance Ministry, Bank Negara Malaysia (BNM), and the Employees Provident Fund (EPF) to develop a health insurance and takaful product. This product will support the rollout of the new Diagnosis-Related Groups (DRGs) system, which aims to transform the way healthcare services are paid for. He also dismissed speculation of a delay in the DRG implementation, adding that the initiative remained on track to be introduced in phases by the end of this year, starting with the "Rakan KKM" project. "This is not privatisation. It is publicly owned and developed for public benefit, offering optional value-added services within the Health Ministry's hospitals. "We are already seeing proof-of-concept through the Hospital Service Outsourcing Programme (HSOP), which applies bundled payment principles. "For example, waiting times for arteriovenous (AV) fistula creation for haemodialysis patients have been reduced by over 75 per cent," he added. Turnaround times for Magnetic Resonance Imaging and Angiography (MRI/MRA) services have also improved by more than 20 per cent, Dzulkefly said, saying these value-based models demonstrated that system efficiency and clinical outcomes could be enhanced. Meanwhile, APHM president Datuk Dr Kuljit Singh highlighted the lack of a national electronic health record system, which he said was a critical gap in the DRG implementation process. "The absence of such a system makes DRG implementation more complex," he said. Nevertheless, he expressed appreciation for the ministry's commitment to collaboration and its data-driven, evidence-based approach to the DRG rollout.


Free Malaysia Today
18 hours ago
- Free Malaysia Today
Cabinet to decide on cannabis-linked vape production by US firm, says Dzulkefly
According to an investor presentation in Las Vegas in April, Ispire Technology Inc produces 'mainly cannabis-related products' in its Malaysian manufacturing facility. (LinkedIn pic) KUALA LUMPUR : The fate of a US-based vape manufacturer producing cannabis-related products in Malaysia will be decided by the Cabinet, says health minister Dzulkefly Ahmad. Speaking on the sidelines of the APHM International Healthcare Conference & Exhibition 2025, Dzulkefly said the issue involving Ispire Technology Inc would require the input of several ministries and government agencies. 'I will have to present (the matter) to the Cabinet. From there, we will decide on a stance. 'Several bodies are involved in this issue such as the investment, trade and industry ministry, the Malaysian Investment Development Authority, and the domestic trade and cost of living ministry,' he told reporters. Health think tank CodeBlue recently reported that Ispire, which produces nicotine and cannabis-related vaping products, had said that its devices were used by clients to fill cartridges with cannabis oils in global markets. According to an investor presentation in Las Vegas in April published on YouTube on May 6, Ispire produces 'mainly cannabis-related products' in its Malaysian manufacturing facility, which has up to seven production lines. In a statement last week, the health ministry confirmed that the government had issued Ispire an interim nicotine manufacturing licence to produce e-cigarettes with nicotine in its plant in Johor, together with local council approval. However, CodeBlue noted that the ministry's June 2 statement did not mention the plant's production of cannabis vaporisers, which reportedly began in February 2024. On June 5, Kuala Langat MP Dr Ahmad Yunus Hairi called for a police investigation into the vape factory's operations. GP consultation fee revision Separately, Dzulkefly said his ministry had submitted its plans to the National Action Council on Cost of Living to address the long-standing issue of revising general practitioner (GP) consultation fees. 'The council has requested that the matter be brought to its executive committee, which is chaired by deputy prime minister Ahmad Zahid Hamidi. 'There is no fixed date for discussions yet, but it will be soon,' he added. Yesterday, the Medical Practitioners Coalition Association of Malaysia (MPCAM) warned the government against deregulating GP consultation fees without setting a minimum rate. MPCAM president Dr Soo Tai Kang said such a move would lead to unhealthy competition in the industry, particularly in urban areas where 80% of GP clinics operate and depend heavily on panel patients. Soo said MPCAM supported setting consultation fees at between RM50 and RM80, with reviews every three years. On June 5, the Malaysian Medical Association called on the government to approve a long-pending increase in GP consultation fees, warning that delays threatened the survival of primary care clinics nationwide. Dzulkefly said on May 3 that the matter would be resolved 'within one month', and that a Cabinet memorandum and circular had already been prepared.